Table 3.

Changes in Parameters of Glycemic Control

	DAPA (n = 36)	Placebo (n = 36)	P
HbA1c, %
Baseline	9.66 ± 1.86	9.31 ± 1.58	0.397
Week 12	8.83 ± 1.50	9.15 ± 1.94	0.438
Change	–0.83 ± 1.47	–0.16 ± 1.26	0.043
P value within group	0.02	0.448
Fasting plasma glucose, mmol/L
Baseline	10.69 ± 4.55	9.57 ± 4.02	0.275
Week 12	8.78 ± 2.98	10.30 ± 4.19	0.080
Change	–1.91 ± 4.40	0.73 ± 4.55	0.015
P value within group	0.013	0.963

P values within groups are results of paired t test or Wilcoxon signed-rank test. P values among groups are results of independent sample t test.

Abbreviations: DAPA, dapagliflozin; HbA1c, hemoglobin A1c.